aibioRevolution Medicines borrows $250.0 million under Royalty Pharma loan
Tickers RVMD
Revolution Medicines borrowed $250.0 million on October 8, 2026, under a senior secured term loan with Royalty Pharma Development Funding, LLC. The loan carries a floating rate of three-month Term SOFR plus 5.75%.
Key facts
- Company
- Revolution Medicines, Inc. (NASDAQ: RVMD)
- News type
- Debt Financing
- Primary source
- Revolution Medicines, Inc. 8-K (2026-10-13)
The Tranche A loan
Revolution Medicines, Inc. borrowed the Tranche A Loan on October 8, 2026, in an aggregate principal amount of $250.0 million, according to a Form 8-K dated October 13. The advance followed U.S. Food and Drug Administration approval of RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
The lender is Royalty Pharma Development Funding, LLC. The loan agreement dated June 23, 2025 names Wilmington Trust, National Association as administrative agent. The facility totals up to $750.0 million in three tranches of up to $250.0 million each, and up to another $500.0 million may be available at the company's election, subject to milestones and to conditions in the agreement. The filing names no placement agent or advisor for the loan, and it names no counsel.
The Tranche A Loan carries a floating rate of three-month Term SOFR, subject to a floor of 3.50%, plus 5.75%. Interest is payable quarterly in arrears. The loan is interest-only, with the principal due October 8, 2032. The company paid the lender a $5.0 million draw fee.
Prepayment is costly early on. The company may prepay only all of the loan at once. Before the second anniversary of the closing, it must pay a make-whole amount equal to interest through that anniversary, plus a 3.0% premium. Between the second and third anniversaries the premium is 3.0%, and after the third anniversary and before maturity it is 1.0%.
The Tranche 3 decision
The company also chose not to take Tranche 3 under a revenue participation right purchase agreement with Royalty Pharma Investments 2019 ICAV. The FDA approval was the trigger for that option, which the company could exercise by delivering a notice no later than October 10, 2026. Had it done so, Royalty Pharma would have paid up to $250.0 million for a corresponding incremental revenue participation right. The company did not deliver the notice, so it will not receive that money. Up to another $500.0 million of purchase price payments remains available at its election, subject to milestones.
What the company is carrying
The annual report shows no revenue for 2025 or 2024. Research and development expense rose to $987.3 million in 2025 from $592.2 million in 2024. The net loss was $1.13 billion for 2025, up from $600.1 million for 2024. Cash used in operations was $897.7 million in 2025, compared with $557.4 million in 2024.
The balance sheet has large liquid assets. Year-end cash and cash equivalents were $543.1 million for 2024 and $383.7 million for 2025, according to a 10-Q filed August 5, 2026. Short-term investments were $1.75 billion at the end of 2024 and $1.64 billion at the end of 2025. At June 30, 2026, cash and cash equivalents were $815.4 million, and short-term investments were $3.12 billion, according to the company's 10-Q.
That makes the borrowing hard to read from the filing alone. The loan costs three-month Term SOFR plus 5.75%, with a 3.50% floor, on $250.0 million, while the company reported $3.12 billion of short-term investments at mid-year. The 8-K does not state a use of proceeds, and it does not explain why the company borrowed now rather than later.
The science and the competition
The annual report describes the company's RAS(ON) inhibitors, and its risk factors are direct about the obstacles. Its product candidates may depart from the conventional treatments that patients and doctors prefer, which could slow enrollment. Its combination programs, including ones with chemotherapy, a PD-1/VEGF bispecific antibody and PRMT5 inhibitors, must show the safety and efficacy of each active component, which the company says may prove challenging. Competitors include large pharmaceutical companies with much greater resources, and the company says approved therapies can take patients who might otherwise join its trials.
What comes next
The 8-K reports no trial data for daraxonrasib. It records the FDA approval and the financing only. The principal falls due on October 8, 2032, and up to $500.0 million more remains available under each agreement if milestones and conditions are met.